SBSapna Bamrah

Sapna Bamrah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sapna Bamrah has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • A. Heetderks

    <label>*</label>Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia

    1 shared publication
  • Alstead Forbes

    Centers for Disease Control and Prevention, Atlanta, GA, USA

    1 shared publication
  • Andrew Heetderks

    Centers for Disease Control and Prevention, Atlanta, GA, USA

    1 shared publication
  • Anne Marie France

    Centers for Disease Control and Prevention, Atlanta, GA, USA

    1 shared publication
  • Edward Desmond

    State of California Department of Public Health Laboratories, Richmond, CA, USA

    1 shared publication
  • F. Dorina

    <label><sup>‡</sup></label>Chuuk State TB Program, Ministry of Health, Chuuk, Federated States of Micronesia

    1 shared publication

Latest Publications

  • Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009–2012

    by S. Bamrah, R. Brostrom, F. Dorina, L. Setik, R. Song, L. M. Kawamura, A. Heetderks, S. Mase

    SETTING: Few studies have shown the operational feasibility, safety, tolerability, or outcomes of multidrug-resistant latent tuberculous infection (MDR LTBI) treatment. After two simultaneous multidrug-resistant tuberculosis (MDR-TB) outbreaks in Chuuk, Federated States of Micronesia, infected contacts were offered a 12-month fluoroquinolone (FQ) based MDR LTBI treatment regimen. DESIGN: Between January 2009 and February 2012, 119 contacts of MDR-TB patients were followed using a prospective observational study design. After MDR-TB disease was excluded, 12 months of daily FQ-based preventive treatment of MDR LTBI was provided by directly observed therapy. RESULTS: Among the 119 infected contacts, 15 refused, while 104 began treatment for MDR LTBI. Of the 104 who initiated treatment, 93 (89%) completed treatment, while 4 contacts discontinued due to adverse effects. None of the 104 contacts who undertook MDR LTBI treatment of any duration developed MDR-TB disease; however, 3 of 15 contacts who refused and 15 unidentified contacts developed MDR-TB disease. CONCLUSION: Providing treatment for MDR LTBI can be accomplished in a resource-limited setting, and contributed to preventing MDR-TB disease. The Chuuk TB program implemented treatment of MDR LTBI with an 89% completion rate. The MDR LTBI regimens were safe and well tolerated, and no TB cases occurred among persons treated for MDR LTBI.


  • Open Access

    Molecular Epidemiology of Mycobacterium tuberculosis in the United States–Affiliated Pacific Islands

    by Sapna Bamrah, Edward Desmond, Smita Ghosh, Anne Marie France, J. Steve Kammerer, Lauren S. Cowan, Andrew Heetderks, Alstead Forbes, Patrick K. Moonan

    The United States–Affiliated Pacific Islands (USAPI) are part of the US National Tuberculosis (TB) Surveillance System and use laboratory services contracted through a cooperative agreement with the Centers for Disease Control and Prevention (CDC). In 2004, the CDC established the National Tuberculosis Genotyping Service, a system to genotype 1 isolate from each culture-confirmed case of TB. To describe the molecular epidemiology of TB in the region, we examined all Mycobacterium tuberculosis isolates submitted for genotyping from January 1, 2004, to December 31, 2008. Over this time period, the USAPI jurisdictions reported 1339 verified TB cases to the National Tuberculosis Surveillance System. Among 419 (31%) reported culture-confirmed TB cases, 352 (84%) had complete genotype results. Routine TB genotyping allowed, for the first time, an exploration of the molecular epidemiology of TB in the USAPI.